fbpx
Fauad Hasan

Fauad Hasan

Investor, Board Member, Entrepreneur

With background in chemical engineering, Fauad comes with more than 19 years of experience in various leadership roles in the Biopharmaceutical industry. Fauad was recently the Co-Founder, President and CEO of Bonti, which was acquired by Allergan (NASDAQ:AGN) in October 2018 for the upfront payment of $195M and subsequent milestone payments. He was instrumental in driving Bonti’s fast progress towards two Phase 2 programs, while raising $36M in multiple financing rounds over a three- year period. Previously, he was the Strategic and Technical leader in R&D group at Allergan, where he served on the Global Product Development teams of top tier neuromodulator (including Botox®) and ocular programs, establishing overall drug development strategy from discovery to commercialization.

Fauad started his career as a scientist at Regeneron Pharmaceuticals (NASDAQ:REGN), where he was part of the R&D team that developed various therapeutic drugs, including a multi-billion dollar revenue ophthalmology drug, Eylea®. He moved on to Baxter International (now part of Takeda) working in roles of increasing responsibilities in the areas of process development, plant engineering, and manufacturing, catering to both internal (including anti-hemophilic FVIII products) and external biologics programs. Fauad is also one of the pioneers of single-use technology, with several patents for Single-use bioreactor (SUB) used in the manufacturing of biologic drugs. Growing up in Silicon Valley, Fauad learned leadership skills at an early age through competitive sports. He won several awards playing squash and cricket at regional and national level, and has represented United States National Cricket team. Currently, he enjoys playing squash and coaching his twin boys youth baseball team. Fauad received his graduate degrees from University of Maryland.